{"id":40014,"date":"2009-11-11T09:37:45","date_gmt":"2009-11-11T14:37:45","guid":{"rendered":"tag:www.hepatitis-central.com,2009:\/mt\/\/1.736"},"modified":"2009-11-11T09:41:00","modified_gmt":"2009-11-11T14:41:00","slug":"boceprevir-study-doubles-hepatitis-c-clearance-rate","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/40014","title":{"rendered":"Boceprevir Study Doubles Hepatitis C Clearance Rate"},"content":{"rendered":"<p>Learn about a phase II trial, whereby Boceprevir was added to standard Hepatitis C therapy (pegylated interferon and ribavirin) and was twice as effective at eliminating the Hep C virus compared to standard therapy alone.<\/p>\n<p>Schering hep C drug promising in Phase II study<\/p>\n<p>By Bill Berkrot<\/p>\n<p>NEW YORK, Nov 1 (Reuters) &#8211; The addition of Schering-Plough Corp&#8217;sSGP.N experimental hepatitis C drug boceprevir after four weeks of treatment with standard medicines led to highly encouraging sustained response rates in a mid-stage study.<\/p>\n<p>The triple combination of boceprevir and the current treatments of pegylated-interferon and ribavirin appeared to knock out the virus at double the rate of the standard drugs alone, according to researchers.<\/p>\n<p>Continue reading the entire article:<br \/>\n<a href=\"http:\/\/www.reuters.com\/article\/rbssHealthcareNews\/idUSN3043814620091101\">http:\/\/www.reuters.com\/article\/rbssHealthcareNews\/idUSN3043814620091101<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Learn about a phase II trial, whereby Boceprevir was added to standard Hepatitis C therapy (pegylated interferon and ribavirin) and was twice as effective at eliminating the Hep C virus compared to standard therapy alone. Schering hep C drug promising in Phase II study By Bill Berkrot NEW YORK, Nov 1 (Reuters) &#8211; The addition [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-40014","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/40014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=40014"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/40014\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=40014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=40014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=40014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}